 Bicycle Therapeutics plc NASDAQ: BCYC, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide Bicycle technology, today announced the appointment of Zafar Qadir as the Companys General Counsel. 